Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice

Molecular and Cellular Endocrinology

Volumn 423, Issue , 2016, Pages 1-10

  González Mariscal, Isabel ^a   Krzysik Walker, Susan M ^a   Kim, Wook ^a,b   Rouse, Michael ^a   Egan, Josephine M ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b Ajou University   (South Korea)

Author keywords

Adenylyl cyclase; CAMP; CB1; GLP 1; Incretin; Insulin secretion

Indexed keywords

ADENYLATE CYCLASE; CANNABINOID 1 RECEPTOR; CYCLIC AMP; ENDOCANNABINOID; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INCRETIN; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ACYLGLYCEROL; AMIDE; ANANDAMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; GLP1R PROTEIN, MOUSE; GLYCERYL 2-ARACHIDONATE; INSULIN; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOWN REGULATION; ENERGY METABOLISM; ENZYME ACTIVITY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULINOMA CELL LINE; INTRAPERITONEAL GLUCOSE TOLERANCE TEST; LIPID DIET; LIPOGENESIS; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BLOCKING; RNA ISOLATION; SIGNAL TRANSDUCTION; SUGAR INTAKE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; C57BL MOUSE; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; PANCREAS ISLET; PHYSIOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

ANIMALS; ARACHIDONIC ACIDS; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CELL LINE, TUMOR; CYCLIC AMP; ENDOCANNABINOIDS; GENETIC PREDISPOSITION TO DISEASE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLYCERIDES; HUMANS; INSULIN; ISLETS OF LANGERHANS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 84957838462     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.12.015     Document Type: Article

References (49)

1. Althage M.C., Ford E.L., Wang S., Tso P., Polonsky K.S., Wice B.M. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J. Biol. Chem. 2008, 283:18365-18376. 10.1074/jbc.M710466200.
2. Anderson R.L., Randall M.D., Chan S.L.F. The complex effects of cannabinoids on insulin secretion from rat isolated islets of. Langerhans. Eur. J. Pharmacol. 2013, 706:56-62. 10.1016/j.ejphar.2013.02.034.
3. Anini Y., Brubaker P.L. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 2003, 52:252-259.
4. Bermúdez-Silva F.J., Suárez J., Baixeras E., Cobo N., Bautista D., Cuesta-Muñoz A.L., Fuentes E., Juan-Pico P., Castro M.J., Milman G., Mechoulam R., Nadal A., Rodríguez de Fonseca F. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008, 51:476-487. 10.1007/s00125-007-0890-y.
5. Bojanowska E., Radziszewska E. Combined stimulation of glucagon-like peptide-1 receptor and inhibition of cannabinoid CB1 receptor act synergistically to reduce food intake and body weight in the rat. J. Physiol. Pharmacol. 2011, 62:395-402.
6. Cheng Y.-H., Ho M.-S., Huang W.-T., Chou Y.-T., King K. Modulation of glucagon-like peptide-1 (GLP-1) potency by endocannabinoid-like lipids represents a novel mode of regulating GLP-1 receptor signaling. J. Biol. Chem. 2015, 290:14302-14313. 10.1074/jbc.M115.655662.
7. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C., Pasquali R., Lutz B., Stalla G.K., Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 2003, 112:423-431. [pii]. 10.1172/JCI17725112/3/423.
8. Di Marzo V., Goparaju S.K., Wang L., Liu J., Bátkai S., Járai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-825. 10.1038/35071088.
9. Drucker D.J., Philippe J., Mojsov S., Chick W.L., Habener J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:3434-3438.
10. Duvivier V.F., Delafoy-Plasse L., Delion V., Lechevalier P., Le Bail J.-C., Guillot E., Pruniaux M.-P., Galzin A.-M. Beneficial effect of a chronic treatment with rimonabant on pancreatic function and beta-cell morphology in Zucker Fatty rats. Eur. J. Pharmacol. 2009, 616:314-320. 10.1016/j.ejphar.2009.05.024.
11. Engeli S. Dysregulation of the endocannabinoid system in obesity. J. Neuroendocrinol. 2008, 20(Suppl. 1):110-115. 10.1111/j.1365-2826.2008.01683.x.
12. Esposito I., Proto M.C., Gazzerro P., Laezza C., Miele C., Alberobello A.T., D'Esposito V., Beguinot F., Formisano P., Bifulco M. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol. Pharmacol. 2008, 74:1678-1686. 10.1124/mol.108.049205.
13. Getty-Kaushik L., Richard A.-M.T., Deeney J.T., Krawczyk S., Shirihai O., Corkey B.E. The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets. Obesity (Silver Spring) 2009, 17:1856-1860. 10.1038/oby.2009.234.
14. Haffner S.M., Miettinen H., Stern M.P. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997, 20:1087-1092.
15. Izzo A.A., Sharkey K.A. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol. Ther. 2010, 126:21-38. 10.1016/j.pharmthera.2009.12.005.
16. Izzo A.A., Piscitelli F., Capasso R., Aviello G., Romano B., Borrelli F., Petrosino S., Di Marzo V. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br. J. Pharmacol. 2009, 158:451-461. 10.1111/j.1476-5381.2009.00183.x.
17. Jourdan T., Godlewski G., Cinar R., Bertola A., Szanda G., Liu J., Tam J., Han T., Mukhopadhyay B., Skarulis M.C., Ju C., Aouadi M., Czech M.P., Kunos G. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat. Med. 2013, 19:1132-1140. 10.1038/nm.3265.
18. (2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006, 39:155-162. 10.1016/j.ceca.2005.10.005.
19. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 2008, 60:470-512. 10.1124/pr.108.000604.
20. Kim W., Doyle M.E., Liu Z., Lao Q., Shin Y.-K., Carlson O.D., Kim H.S., Thomas S., Napora J.K., Lee E.K., Moaddel R., Wang Y., Maudsley S., Martin B., Kulkarni R.N., Egan J.M. Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells. Diabetes 2011, 60:1198-1209. 10.2337/db10-1550.
21. Kim W., Lao Q., Shin Y.K., Carlson O.D., Lee E.K., Gorospe M., Kulkarni R.N., Egan J.M. Cannabinoids induce pancreatic beta-cell death by directly inhibiting insulin receptor activation. Sci. Signal. 2012, 5(ra23). [pii]. 10.1126/scisignal.20025195/216/ra23.
22. Li C., Jones P.M., Persaud S.J. Cannabinoid receptors are coupled to stimulation of insulin secretion from mouse MIN6 beta-cells. Cell. Physiol. Biochem. 2010, 26:187-196. 10.1159/000320527.
23. Li C., Bowe J.E., Huang G.C., Amiel S.A., Jones P.M., Persaud S.J. Cannabinoid receptor agonists and antagonists stimulate insulin secretion from isolated human islets of Langerhans. Diabetes Obes. Metab. 2011, 13:903-910. 10.1111/j.1463-1326.2011.01422.x.
24. Lu W.J., Yang Q., Sun W., Woods S.C., D'Alessio D., Tso P. The regulation of the lymphatic secretion of glucagon-like peptide-1 (GLP-1) by intestinal absorption of fat and carbohydrate. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293:G963-G971. 10.1152/ajpgi.00146.2007.
25. Malenczyk K., Jazurek M., Keimpema E., Silvestri C., Janikiewicz J., Mackie K., Di Marzo V., Redowicz M.J., Harkany T., Dobrzyn A. CB1 cannabinoid receptors couple to focal adhesion kinase to control insulin release. J. Biol. Chem. 2013, 288:32685-32699. 10.1074/jbc.M113.478354.
26. Matias I., Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol. Metab. 2007, 18:27-37. S1043-2760(06)00243-8 [pii]. 10.1016/j.tem.2006.11.006.
27. Matias I., Gonthier M.-P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., Petrosino S., Hoareau L., Festy F., Pasquali R., Roche R., Maj M., Pagotto U., Monteleone P., Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 2006, 91:3171-3180. 10.1210/jc.2005-2679.
28. Montrose-Rafizadeh C. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J. Biol. Chem. 1997, 272:21201-21206. 10.1074/jbc.272.34.21201.
29. Montrose-Rafizadeh C., Egan J.M., Roth J. Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action. Endocrinology 1994, 135:589-594. 10.1210/endo.135.2.8033807.
30. Moss C.E., Marsh W.J., Parker H.E., Ogunnowo-Bada E., Riches C.H., Habib A.M., Evans M.L., Gribble F.M., Reimann F. Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia 2012, 55:3094-3103. 10.1007/s00125-012-2663-5.
31. 2+ oscillation in islet beta-cells via CB1 receptors. Regul. Pept. 2008, 145:49-53. S0167-0115(07)00157-7 [pii]. 10.1016/j.regpep.2007.08.009.
32. Nam D.H., Lee M.H., Kim J.E., Song H.K., Kang Y.S., Lee J.E., Kim H.W., Cha J.J., Hyun Y.Y., Kim S.H., Han S.Y., Han K.H., Han J.Y., Cha D.R. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology 2012, 153:1387-1396. [pii]. 10.1210/en.2011-1423en.2011-1423.
33. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Bátkai S., Harvey-White J., Mackie K., Offertáler L., Wang L., Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 2005, 115:1298-1305. 10.1172/JCI23057.
34. Patel K.N., Joharapurkar A.A., Patel V., Kshirsagar S.G., Bahekar R., Srivastava B.K., Jain M.R. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice. Can. J. Physiol. Pharmacol. 2014, 92:975-983. 10.1139/cjpp-2014-0310.
35. Powell D.R., Gay J.P., Wilganowski N., Doree D., Savelieva K.V., Lanthorn T.H., Read R., Vogel P., Hansen G.M., Brommage R., Ding Z.-M., Desai U., Zambrowicz B. Diacylglycerol lipase α knockout mice demonstrate metabolic and behavioral phenotypes similar to those of cannabinoid receptor 1 knockout mice. Front. Endocrinol. (Lausanne) 2015, 6:86. 10.3389/fendo.2015.00086.
36. Radziszewska E., Wolak M., Bojanowska E. Concurrent pharmacological modification of cannabinoid-1 and glucagon-like peptide-1 receptor activity affects feeding behavior and body weight in rats fed a free-choice, high-carbohydrate diet. Behav. Pharmacol. 2014, 25:53-60. 10.1097/FBP.0000000000000018.
37. Ravinet Trillou C., Delgorge C., Menet C., Arnone M., Soubrié P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 2004, 28:640-648. 10.1038/sj.ijo.0802583.
38. Rizzo M.A., Piston D.W. High-contrast imaging of fluorescent protein FRET by fluorescence polarization microscopy. Biophys. J. 2005, 88:L14-L16. 10.1529/biophysj.104.055442.
39. Silvestri C., Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013, 17:475-490. [pii]. 10.1016/j.cmet.2013.03.001S1550-4131(13)00103-4.
40. Starowicz K.M., Cristino L., Matias I., Capasso R., Racioppi A., Izzo A.A., Di Marzo V. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008, 16:553-565. 10.1038/oby.2007.106.
41. Sykaras A.G., Demenis C., Case R.M., McLaughlin J.T., Smith C.P. Duodenal enteroendocrine I-cells contain mRNA transcripts encoding key endocannabinoid and fatty acid receptors. PLoS One 2012, 7:e42373. 10.1371/journal.pone.0042373.
42. Tam J., Vemuri V.K., Liu J., Batkai S., Mukhopadhyay B., Godlewski G., Osei-Hyiaman D., Ohnuma S., Ambudkar S.V., Pickel J., Makriyannis A., Kunos G. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J. Clin. Invest. 2010, 120:2953-2966. [pii]. 10.1172/JCI4255142551.
43. Tam J., Cinar R., Liu J., Godlewski G., Wesley D., Jourdan T., Szanda G., Mukhopadhyay B., Chedester L., Liow J.-S., Innis R.B., Cheng K., Rice K.C., Deschamps J.R., Chorvat R.J., McElroy J.F., Kunos G. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 2012, 16:167-179. 10.1016/j.cmet.2012.07.002.
44. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:8641-8645.
45. Troy-Fioramonti S., Demizieux L., Gresti J., Muller T., Vergès B., Degrace P. Acute activation of cannabinoid receptors by anandamide reduces gastro-intestinal motility and improves postprandial glycemia in mice. Diabetes 2014, 10.2337/db14-0721.
46. Turu G., Hunyady L. Signal transduction of the CB1 cannabinoid receptor. J. Mol. Endocrinol. 2010, 44:75-85. 10.1677/JME-08-0190.
47. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397. 10.1016/S0140-6736(05)66374-X.
48. Wang Y., Perfetti R., Greig N.H., Holloway H.W., DeOre K.A., Montrose-Rafizadeh C., Elahi D., Egan J.M. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J. Clin. Invest. 1997, 99:2883-2889. 10.1172/JCI119482.
49. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5780-5785.